Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Revolution Medicines Inc

RVMD ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Large Cap Analyst: BUY

Last Close

$210.02

▼ -0.40%

Market Cap $45.01B · Vol 288.82K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$45.01B

Large Cap

Div Yield

N/A

EPS Growth

-62.95%

YoY

RSI (14)

47.83

Momentum

Beta

1.40

vs Market

52W High

$224.24

6.34% below

52W Low

$39.29

434.54% above

Volume

288.82K

Avg 538.30K

P/B

9.62

Price-to-book

ROE

-58.07%

Return on equity

Free Float

97.55%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Revolution Medicines Inc (RVMD) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RVMD pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.03%

+8.56%

+34.90%

+107.55%

YTD

+163.68%

+439.20%

+523.39%

+621.72%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-1,131,301,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-58.07%
ROA · ROIC	-46.06% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	9.62
P/FCF	N/A
EPS Growth	-62.95%
Outstanding Shares	214.34M

Technical Indicators

50-Day SMA	$196.79
200-Day SMA	$134.06
RSI (14)	47.83
Beta	1.40
52-Week High	$224.24
52-Week Low	$39.29

Volume Today	288.82K
Avg Daily Volume (30D)	538.30K
Relative Volume	0.54x
Volatility (10D)	37.47
Volatility (30D)	39.74
Free Float	97.55%

Analyst Consensus

BUY

Current Price $210.02

Mean Target $250.70

52W Low$39.29 52W High$224.24

Current

Target

$39.29 $224.24

Current Analyst target

+19.37% upside potential · 22 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00829F4Q7

ISINUS76155X1000

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -2.54% ONC BeOne Medicines AG -1.22% 068270.KS Celltrion Inc +0.53% ABVX Abivax SA +0.66% ABVX.PA Abivax SA -1.56%

Company Profile

Revolution Medicines, Inc. is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The Company's research and development pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The Company is advancing a pipeline of RAS(ON) Inhibitors, daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor are in clinical development. The Company's pipeline also focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). The Daraxonrasib, our RAS(ON) multi-selective inhibitor, is designed as an oral, tri-complex inhibitor of multiple RAS(ON) variants containing cancer driver mutations at all three of the major RAS mutation hotspot positions, G12, G13, and Q61.